產(chǎn)品目錄

規(guī)格	10mM500mg 1g
CAS	80621-81-4
別名	N/A
化學名	N/A
分子式	C43H51N3O11
分子量	785.88
溶解度	≥ 83.3mg/mL in DMSO
儲存條件	Store at 2-8°C
General tips	For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping Condition	Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request

產(chǎn)品描述：

Rifaximin, a rifamycin derivative, is a nonabsorbable antibiotic. Rifaximin inhibits RNA synthesis by binding the β subunit of the bacterial DNA-dependent RNA polymerase.

In vitro:Rifaximin, a gut-specific ligand for the human nuclear receptor pregnane-X receptor (PXR), contributes to the maintenance of the intestinal immune homeostasis. Rifaximin abrogates the binding of NF-κB caused by LPS. In human colon biopsies from inflammatory bowel diseases patients, exposure of rifaximin (100 μM) reduced mRNA levels of IL-8, Rantes, MIP-3α and TNFα induced by LPS stimulation [1]. Rifaximin acted on the β subunit of the deoxyribonucleic acid (DNA)-dependent ribonucleic acid (RNA) polymerase enzyme of bacteria to inhibit bacterial RNA synthesis. The susceptibility of Gram-positive organisms to rifaximin was greater than that of Gram-negative organisms [2]. In the DPX2 cell line transfected with stable recombinant human PXR expression, hPXR was significantly activated at RIFax concentrations over 1 μM and the EC50 was about 20 μM[3].

In vivo:In the small intestine of hPXR mice treated with rifaximin, several PXR target genes such as CYP3A11, GSTA1, MRP2, and OATP2 were up-regulated. Rifaximin treatment demonstrated no significant effect on hepatic PXR target genes in wild-type, Pxr-null, and hPXR mice [3]. In PXR-humanized mice, long-term administration of rifaximin for 6 months on the liver up-regulated the expression of hepatic genes related to triglyceride synthesis and lipid accumulation [4].

Clinical trials: Over a 6-month period, treatment with rifaximin maintained remission from hepatic encephalopathy effectively. Rifaximin treatment also significantly reduced the risk of hospitalization involving hepatic encephalopathy [5]. Among patients with irritable bowel syndrome (IBS) without constipation, treatment with rifaximin for 2 weeks provided significant relief of IBS symptoms, bloating, abdominal pain, and loose or watery stools [6]. Rifaximin could improve the symptom in IBS patients, such as abdominal bloating and flatulence [7].

特別提醒：

1. 本產(chǎn)品僅供科研使用。請勿用于醫(yī)藥、臨床診斷或治療，食品及化妝品等用途。請勿存放于普通住宅區(qū)。

2. 為了您的安全和健康，請穿好實驗服并佩戴一次性手套和口罩操作。

原創(chuàng)作者：上海莼試生物技術有限公司

在線咨詢

留言注意事項：

1.遵守中華人民共和國有關法律、法規(guī)，尊重網(wǎng)上道德，承擔一切因您的行為而直接或間接引起的法律責任。

2.請您真實的反映產(chǎn)品的情況,不要捏造、誣蔑、造謠。如對產(chǎn)品有任何疑問,也可以留言咨詢。

3.未經(jīng)本站同意，任何人不得利用本留言簿發(fā)布個人或團體的具有廣告性質(zhì)的信息或類似言論。

您感興趣的產(chǎn)品*
您的單位*
聯(lián)系人*
聯(lián)系電話*
詳細地址*
常用郵箱*
請輸入您對我們的意見或建議*
驗證碼*